NCT04733833View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 26, 2021

Primary Completion Date

October 25, 2022

Study Completion Date

October 25, 2022

Conditions
Severe COVID-19
Interventions
DRUG

VB-201 + Standard of care

Daily oral administration of VB-201- 160 mg (80 mg BID) with standard of care

DRUG

Standard of care

Standard of care

Trial Locations (1)

5262000

Chaim Sheba Medical Center, Ramat Gan

All Listed Sponsors
lead

Vascular Biogenics Ltd. operating as VBL Therapeutics

INDUSTRY

NCT04733833 - A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19 | Biotech Hunter | Biotech Hunter